These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 34546844)

  • 21. Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial.
    Maruyama D; Tobinai K; Chou T; Taniwaki M; Shumiya Y; Iida S
    Cancer Sci; 2018 Oct; 109(10):3245-3252. PubMed ID: 30058108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
    Chim CS; Kumar S; Wong VKC; Ngai C; Kwong YL
    Hematology; 2021 Dec; 26(1):652-655. PubMed ID: 34474661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.
    Kumar SK; Majer I; Panjabi S; Medhekar R; Campioni M; Dimopoulos MA
    Expert Rev Hematol; 2020 Jun; 13(6):687-696. PubMed ID: 32249621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
    Gasparetto C; Schiller GJ; Tuchman SA; Callander NS; Baljevic M; Lentzsch S; Rossi AC; Kotb R; White D; Bahlis NJ; Chen CI; Sutherland HJ; Madan S; LeBlanc R; Sebag M; Venner CP; Bensinger WI; Biran N; Ammu S; Ben-Shahar O; DeCastro A; Van Domelen D; Zhou T; Zhang C; Bentur OS; Shah J; Shacham S; Kauffman M; Lipe B
    Br J Cancer; 2022 Mar; 126(5):718-725. PubMed ID: 34802051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
    Monteith BE; Venner CP; Cheung MC; Pater J; Shepherd L; Richardson H; Reece D; Gul E; Lalancette M; Castonguay V; Kukreti V; Tiedemann R; Phua C; Bhella S; Dudebout J; Sherry M; Yen H; Chen BE; Hay AE
    Eur J Haematol; 2021 Sep; 107(3):333-342. PubMed ID: 34053112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
    Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
    JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data.
    Weisel K; Ludwig H; Rieth A; Lebioda A; Goldschmidt H
    Qual Life Res; 2020 Jan; 29(1):69-79. PubMed ID: 31552577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
    Davies F; Rifkin R; Costello C; Morgan G; Usmani S; Abonour R; Palumbo A; Romanus D; Hajek R; Terpos E; Cherepanov D; Stull DM; Huang H; Leleu X; Berdeja J; Lee HC; Weisel K; Thompson M; Boccadoro M; Zonder J; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A
    Ann Hematol; 2021 Sep; 100(9):2325-2337. PubMed ID: 33970288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.
    Dimopoulos MA; Kaufman JL; White D; Cook G; Rizzo M; Xu Y; Fahrbach K; Gaudig M; Slavcev M; Dearden L; Lam A
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):163-173.e6. PubMed ID: 29456035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
    Chari A; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Lunning M; Usmani SZ; Anderson LD; Chhabra S; Girnius S; Shustik C; Stuart R; Lee Y; Salman Z; Liu E; Valent J
    Hematol Oncol; 2020 Aug; 38(3):353-362. PubMed ID: 32053229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma.
    Siegel D; Weisel K; Zahlten-Kumeli A; Medhekar R; Ding B; Leleu X
    Leuk Lymphoma; 2021 Dec; 62(12):3002-3010. PubMed ID: 34180331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
    Du J; Fang B; Li J; Jin J; Wang S; Zou D; Cai Z; Wang H; Hu J; Li W; Fu C; Shao Z; Xia Z; Liu P; Niu T; Tang ET; Kimball AS; Hou J; Chen W
    Int J Hematol; 2021 Mar; 113(3):422-429. PubMed ID: 33389656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-weekly
    Bringhen S; Mina R; Petrucci MT; Gaidano G; Ballanti S; Musto P; Offidani M; Spada S; Benevolo G; Ponticelli E; Galieni P; Cavo M; Di Toritto TC; Di Raimondo F; Montefusco V; Palumbo A; Boccadoro M; Larocca A
    Haematologica; 2019 Aug; 104(8):1640-1647. PubMed ID: 30733270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.
    Suzuki K; Ri M; Chou T; Sugiura I; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Ota K; Iida S
    Cancer Sci; 2017 Mar; 108(3):461-468. PubMed ID: 28092421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
    Xu W; Sun X; Wang B; Guo H
    Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
    Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
    Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
    Jakubowiak A; Usmani SZ; Krishnan A; Lonial S; Comenzo RL; Wang J; de Boer C; Deraedt W; Weiss BM; Schecter JM; Chari A
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):701-710. PubMed ID: 34274290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
    Moreau P; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Risse ML; Asset G; Macé S; Martin T;
    Lancet; 2021 Jun; 397(10292):2361-2371. PubMed ID: 34097854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.